Literature DB >> 23159943

miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin β3.

Noritoshi Honda1, Masatoshi Jinnin, Tomomi Kira-Etoh, Katsunari Makino, Ikko Kajihara, Takamitsu Makino, Satoshi Fukushima, Yuji Inoue, Yoshinobu Okamoto, Minoru Hasegawa, Manabu Fujimoto, Hironobu Ihn.   

Abstract

Overexpression of integrins in dermal fibroblasts is thought to play a key role in the pathogenesis of systemic sclerosis (SSc), but the mechanism is unknown. We evaluated the possibility that microRNAs (miRNAs) are involved in the regulation of integrin β3 in these cells. The miRNA expression profile was determined by miRNA PCR array and real-time PCR. Protein expression of integrin β3 was determined by immunoblotting. In vivo detection of miRNA in paraffin section was performed by in situ hybridization. miR-150 expression was decreased in SSc fibroblasts both in vivo and in vitro. The transfection of miR-150 inhibitor into normal fibroblasts induced expression of integrin β3, phosphorylated Smad3, and type I collagen, whereas forced overexpression of the miRNA resulted in their down-regulation in SSc fibroblasts. Treatment of SSc fibroblasts with 5-AdC revealed that miR-150 down-regulation in these cells is caused by DNA methylation. In addition, we found that miR-150 is detectable and quantitative in serum. Serum miR-150 levels were decreased in SSc patients, and the SSc patients with lower serum miR-150 levels tended to have more severe clinical manifestations. miR-150 may play an important role in the pathogenesis of SSc via overexpression of integrin β3. Investigation of the regulatory mechanisms of tissue fibrosis by miR-150 could lead to development of new diagnostic tools and new treatments using miRNA.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159943     DOI: 10.1016/j.ajpath.2012.09.023

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

Review 1.  The role of microRNAs in skin fibrosis.

Authors:  Olubukola Babalola; Andrew Mamalis; Hadar Lev-Tov; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2013-11       Impact factor: 3.017

Review 2.  The sex bias in systemic sclerosis: on the possible mechanisms underlying the female disease preponderance.

Authors:  Fabio D'Amico; Evangelia Skarmoutsou; Maria Clorinda Mazzarino
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

3.  Effects of miR-150-5p on the growth and SOCS1 expression of rheumatoid arthritis synovial fibroblasts.

Authors:  Mingliang Qiu; Lisha Mo; Juxiang Li; Hua Liang; Weina Zhu; Xiangjuan Zheng; Xinwang Duan; Weidong Xu
Journal:  Clin Rheumatol       Date:  2019-12-26       Impact factor: 2.980

Review 4.  Fibrosis--a lethal component of systemic sclerosis.

Authors:  Yuen Yee Ho; David Lagares; Andrew M Tager; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2014-04-22       Impact factor: 20.543

Review 5.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 6.  Epigenetics in Non-tumor Immune-Mediated Skin Diseases.

Authors:  M C Ovejero-Benito; E Daudén; Alejandra Reolid; E Muñoz-Aceituno; F Abad-Santos
Journal:  Mol Diagn Ther       Date:  2021-03-01       Impact factor: 4.074

Review 7.  TGF-β1 Signaling and Tissue Fibrosis.

Authors:  Kevin K Kim; Dean Sheppard; Harold A Chapman
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

8.  MiR-3606-3p inhibits systemic sclerosis through targeting TGF-β type II receptor.

Authors:  Xiangguang Shi; Qingmei Liu; Na Li; Wenzhen Tu; Ruoyu Luo; Xueqian Mei; Yanyun Ma; Weihong Xu; Haiyan Chu; Shuai Jiang; Zhimin Du; Han Zhao; Liang Zhao; Li Jin; Wenyu Wu; Jiucun Wang
Journal:  Cell Cycle       Date:  2018-09-17       Impact factor: 4.534

9.  Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Authors:  Coralie Hoareau-Aveilla; Thibaud Valentin; Camille Daugrois; Cathy Quelen; Géraldine Mitou; Samuel Quentin; Jinsong Jia; Salvatore Spicuglia; Pierre Ferrier; Monica Ceccon; Sylvie Giuriato; Carlo Gambacorti-Passerini; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

10.  Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.

Authors:  Xiongbo Wu; Min Xia; Dayang Chen; Fang Wu; Zhifa Lv; Qiang Zhan; Yang Jiao; Wenjie Wang; Guangxia Chen; Fangmei An
Journal:  Tumour Biol       Date:  2016-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.